Egypt Interventional Cardiology Devices Market Size & Outlook, 2025-2033
Egypt Interventional Cardiology Devices Market Insights
- As highlighted in Reed Intelligence analysis, the Egypt Interventional Cardiology Devices Market, worth USD 122.87 Million in 2024, is forecasted to achieve USD 222.86 Million by 2033.
- The Egypt market is anticipated to grow at a CAGR of 6.79% during the period 2025–2033.
- By 2024, Coronary Stents represented the largest share of the By Product Type market size.
- Coronary Stents is expected to remain the key growth driver within By Product Type, registering the fastest CAGR during the forecast period.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2024, Egypt accounted for 0.86% of the global Interventional Cardiology Devices Market size.
- By 2033, United States is expected to lead the global Interventional Cardiology Devices Market in terms of market size.
- Within Middle East and Africa, United Arab Emirates is projected to dominate the regional Interventional Cardiology Devices Market size by 2033.
- Turkey is identified as the fastest-growing market in Middle East and Africa, anticipated to reach USD 160.87 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 122.87 Million |
| Market Size In 2033 | USD 222.86 Million |
| Largest segment | Coronary Stents |
| Units | Revenue in USD Million |
| CAGR | 6.79% (2025-2033) |
| Segmnetation Covered | |
| By Product Type |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Egypt Interventional Cardiology Devices Market By Product Type 2025-2033 (USD Million)
| By Product Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coronary Stents | XX.x | XX.x | XX.x | 50.76 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Catheters | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloons | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Percutaneous Transluminal Coronary Angioplasty (PTCA) Guide Wires | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Other Product Types | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
